Article citationsMore>>

Rosenstock, J., Balas, B., Charbonnel, B., et al. (2013) The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, versus Twice-Daily Exenatide for Type 2 Diabetes the T-Emerge 2 Trial. Diabetes Care, 36, 498-504.
https://doi.org/10.2337/dc12-0709

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top